Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sanofi pasteur - influenza a virus subtype h1n1 haemagglutinin, recombinant, influenza a virus subtype h3n2 haemagglutinin, recombinant, influenza b virus victoria lineage haemagglutinin, recombinant, influenza b virus yamagata lineage haemagglutinin, recombinant - influwenza, bniedem - vaċċini - supemtek is indicated for active immunization for the prevention of influenza disease in adults. supemtek should be used in accordance with official recommendations.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

intervacc ab - recombinant streptococcus equi protein cce, recombinant streptococcus equi protein eq85, recombinant streptococcus equi protein idee - immunoloġiċi għall-equidae - Żwiemel - for the active immunisation to reduce clinical signs and the number of abscesses in acute stage of infection with s. equi.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

hipra human health s.l. - sars-cov-2 virus recombinant spike (s) protein receptor binding domain (rbd) fusion heterodimer – b.1.351-b.1.1.7 strains - covid-19 virus infection - vaċċini - bimervax is indicated as a booster for active immunisation to prevent covid-19 in individuals 16 years of age and older who have previously received a mrna covid-19 vaccine.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

leti pharma, s.l.u. - recombinant protein q from leishmania infantum mon-1 - vaċċini batterjali inattivati (inkluż mycoplasma, toxoid u chlamydia) - klieb - għal immunizzazzjoni attiva ta 'klieb minn 6 xhur ta' età biex jitnaqqas ir-riskju li jiġi żviluppat każ kliniku ta 'leishmaniasis.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

glaxosmithkline biologicals sa - recombinant varicella zoster virus glycoprotein e - herpes zoster - vaċċini - shingrix is indicated for prevention of herpes zoster (hz) and post-herpetic neuralgia (phn), in:adults 50 years of age or older;adults 18 years of age or older at increased risk of hz. l-użu ta shingrix għandha tkun skond ir-rakkomandazzjonijiet uffiċjali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant adenovirus type 26 (ad26) encoding the glycoprotein (gp) of the ebola virus zaire (zebov) mayinga strain - emorraġiku-deni, l-ebola - vaċċini - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant modified vaccinia ankara bavarian nordic virus encoding the: ebola virus zaire (zebov) mayinga strain glycoprotein (gp); ebola virus sudan gulu strain gp; ebola virus taï forest strain nucleoprotein and the marburg virus musoke strain gp - emorraġiku-deni, l-ebola - vaċċini - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

ceva-phylaxia co. ltd. - recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus, live - chicken - for active immunisation of chickens from 8 weeks of age in order to reduce the skin lesions due to fowlpox and to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a.  - respiratory syncytial virus recombinant glycoprotein f stabilised in the pre-fusion conformation (rsvpref3) produced in chinese hamster ovary (cho) cells by recombinant dna technology - infezzjonijiet ta 'virus sintetiku respiratorju - vaċċini - arexvy is indicated for active immunisation for the prevention of lower respiratory tract disease (lrtd) caused by respiratory syncytial virus in adults 60 years of age and older. l-użu ta ' dan il-vaċċin għandha tkun skond ir-rakkomandazzjonijiet uffiċjali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sanofi pasteur msd, snc - polyribosylribitol phosphate mill-haemophilus influenzae tat-tip b bħala prp-ompc, il-membrana ta 'barra kumpless tal-proteina tal neisseria meningitidis (il-membrana ta' barra kumpless tal-proteina tar-razza b11 ta 'neisseria meningitidis sottogrupp b), adsorbit ta' l-epatite b-antiġen tal-wiċċ prodott f'ċelloli tal-ħmira rikombinanti (saccharomyces cerevisiae) - hepatitis b; meningitis, haemophilus; immunization - vaċċini - procomvax huwa indikat għall-vaċċinazzjoni kontra l-marda invażivi ikkawżat minn influwenza Ħemofillika tip b u kontra l-infezzjoni kkawżat mill-sottotipi magħrufa kollha tal-virus tal-hepatitis b fit-trabi 6 ġimgħat sa 15-il xahar.